ArticleOncoTargets and therapy2015

NVP-BEZ235 overcomes gefitinib-acquired resistance by down-regulating PI3K/AKT/mTOR phosphorylation.

Zhihua Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.